Overview

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Treatments:

Apatinib